Jerusalem Pharmaceuticals Co. Ltd. (PEX:JPH)
Palestine · Delayed Price · Currency is JOD · Price in USD 3.680
0.00 (0.00%)
At close: Jun 17, 2026
Jerusalem Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 48.95 | 39.82 | 39.65 | 46.14 | 46.23 | |
Revenue Growth (YoY) | 22.91% | 0.42% | -14.06% | -0.18% | 27.00% |
Cost of Revenue | 21.43 | 19.7 | 18.31 | 23 | 23.44 |
Gross Profit | 27.52 | 20.12 | 21.34 | 23.14 | 22.79 |
Selling, General & Admin | 12.05 | 10.52 | 10.77 | 12.23 | 12.57 |
Research & Development | 1.44 | 1.12 | 0.93 | 1.73 | 1.74 |
Other Operating Expenses | 0.44 | -0.09 | -0.15 | -0.26 | 0.07 |
Operating Expenses | 14.67 | 13.42 | 12.36 | 14.33 | 14.81 |
Operating Income | 12.85 | 6.7 | 8.98 | 8.81 | 7.98 |
Interest Expense | -0.01 | -0.02 | -0.04 | -0.06 | -0.06 |
Interest & Investment Income | - | - | - | 0.03 | 0.02 |
Earnings From Equity Investments | - | - | - | - | -0 |
Currency Exchange Gain (Loss) | -1.29 | -0.64 | -0.08 | 0.36 | -0.21 |
Other Non Operating Income (Expenses) | -0.27 | -0.29 | -0.19 | -0.14 | -0.16 |
EBT Excluding Unusual Items | 11.27 | 5.76 | 8.68 | 9 | 7.57 |
Gain (Loss) on Sale of Investments | 1.56 | 0.84 | 0.04 | 0 | 0 |
Gain (Loss) on Sale of Assets | -0 | 0 | 0.11 | - | 0.01 |
Other Unusual Items | 0.01 | 0.02 | - | 0.03 | 0.04 |
Pretax Income | 12.83 | 6.62 | 8.82 | 9.03 | 7.62 |
Income Tax Expense | 2.58 | 1.56 | 1.81 | 1.82 | 1.4 |
Earnings From Continuing Operations | 10.26 | 5.06 | 7.01 | 7.21 | 6.22 |
Earnings From Discontinued Operations | - | - | - | -0.21 | - |
Net Income to Company | 10.26 | 5.06 | 7.01 | 7 | 6.22 |
Minority Interest in Earnings | -0.07 | -0.02 | -0.05 | 0.17 | 0.38 |
Net Income | 10.18 | 5.04 | 6.96 | 7.17 | 6.6 |
Net Income to Common | 10.18 | 5.04 | 6.96 | 7.17 | 6.6 |
Net Income Growth | 102.13% | -27.58% | -3.02% | 8.73% | 77.11% |
Shares Outstanding (Basic) | 36 | 36 | 36 | 36 | 36 |
Shares Outstanding (Diluted) | 36 | 36 | 36 | 36 | 36 |
EPS (Basic) | 0.28 | 0.14 | 0.19 | 0.20 | 0.18 |
EPS (Diluted) | 0.28 | 0.14 | 0.19 | 0.20 | 0.18 |
EPS Growth | 102.13% | -27.58% | -3.02% | 8.73% | 77.11% |
Free Cash Flow | 1.61 | 9.94 | 7.84 | 16.32 | 3.86 |
Free Cash Flow Per Share | 0.04 | 0.28 | 0.22 | 0.45 | 0.11 |
Dividend Per Share | 0.075 | 0.040 | 0.050 | 0.075 | 0.060 |
Dividend Growth | 87.50% | -20.00% | -33.33% | 25.00% | 50.00% |
Gross Margin | 56.22% | 50.52% | 53.82% | 50.15% | 49.30% |
Operating Margin | 26.25% | 16.83% | 22.65% | 19.09% | 17.25% |
Profit Margin | 20.80% | 12.65% | 17.54% | 15.55% | 14.27% |
Free Cash Flow Margin | 3.29% | 24.96% | 19.77% | 35.37% | 8.35% |
EBITDA | 14.38 | 7.95 | 10.17 | 10.53 | 9.94 |
EBITDA Margin | 29.39% | 19.95% | 25.65% | 22.83% | 21.50% |
D&A For EBITDA | 1.54 | 1.24 | 1.19 | 1.73 | 1.96 |
EBIT | 12.85 | 6.7 | 8.98 | 8.81 | 7.98 |
EBIT Margin | 26.25% | 16.83% | 22.65% | 19.09% | 17.25% |
Effective Tax Rate | 20.08% | 23.52% | 20.55% | 20.18% | 18.42% |
Advertising Expenses | 0.07 | 0.02 | 0.01 | 0.06 | 0.05 |